CompletedPhase 4

Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage

United States16 participantsStarted 2014-12

Plain-language summary

The purpose of this study is to see how much gabapentin will reduce headaches associated with subarachnoid hemorrhage (SAH) and to reduce the amount of narcotic pain medication prescribed.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. 18 years of age or older
✓. Have aneurysmal subarachnoid hemorrhage (aSAH) diagnosed by CT scan of the brain and/or angiogram evidence of intracranial aneurysm (CTA or digital subtraction angiogram or MRA)
✓. Have symptomatic headache
✓. Able to swallow and verbalize pain score
✓. No known allergy to gabapentin or fentanyl
✓. Numeric pain score ≥ 5
✓. Ability to provide written personal consent

Exclusion criteria

✕. Gabapentin use prior to SAH admission
✕. Renal failure with creatinine clearance less than 30 mL/min
✕. Unable to receive standard of care pain medications
✕. Pregnant or breastfeeding patients
✕. History of severe depression defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM IV)

What they're measuring

Average Numeric Pain Score

Timeframe: baseline through day 7

Average Narcotic Consumption

Timeframe: baseline through day 7

Trial details

NCT IDNCT02330094

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-09-01

Results submitted2019-04-15

View on ClinicalTrials.gov More Aneurysmal Subarachnoid Hemorrhage trials